Plant Name: Achillea millefolium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| PTPN1; | |
| TDP1; PKM; HSD17B1; HSD17B10; NOX4; ALOX15; USP2; TNKS2; TNKS; | |
| ACHE; | |
| CFTR; | |
| GSK3B; SYK; CDK6; FLT3; PRKCA; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA5B; CA14; CA3; CA5A; CA6; CA7; | |
| AR; | |
| ESR2; ESR1; | |
| THRB; | |
| MAOA; PTGS2; XDH; | |
| MMP9; MMP1; MMP2; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; ABCC1; | |
| LMNA; NPC1; MAPT; THPO; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.263E-11 | 5.157E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.796E-09 | 2.029E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.027E-09 | 3.071E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.220E-08 | 6.639E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.396E-08 | 7.239E-06 | CA2, CA7, CFTR, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.627E-08 | 8.013E-06 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, XDH |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.888E-08 | 1.971E-05 | AR, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4, NPC1, PTGS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.589E-07 | 5.671E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.396E-07 | 1.013E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.343E-07 | 1.228E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 7.584E-07 | 1.898E-04 | PKM, THRB, TTR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 7.984E-07 | 1.976E-04 | CA2, CA7, CDK6, CFTR, HIF1A, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 8.931E-07 | 2.137E-04 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, MMP2, MMP9, PRKCA, PTGS2, SYK, THPO, TSHR |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.324E-06 | 2.972E-04 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.585E-06 | 5.260E-04 | CA2, CA7, CFTR |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 3.547E-06 | 7.021E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.719E-06 | 9.192E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 4.868E-06 | 9.381E-04 | AR, CFTR, CYP1A1, CYP1A2, CYP2C19, CYP3A4, ESR1, ESR2, GSK3B, HIF1A, MAPT, PRKCA, PTGS2, PTPN1, SYK, THRB, TNKS2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 5.682E-06 | 1.085E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.961E-06 | 1.457E-03 | ESR1, ESR2 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.086E-05 | 1.922E-03 | CA5A, CA5B, CYP1A1, CYP1B1, ESR2, GSK3B, HSD17B10, MAOA, MMP2, NFKB1, NOX4, PKM, PRKCA, TP53 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 1.274E-05 | 2.150E-03 | ALOX15, AR, FLT3, NOX4, PRKCA, PTPN1, SYK, THPO, XDH |
| BP | GO:0065007; biological regulation | GO:0044093; positive regulation of molecular function | 1.849E-05 | 2.835E-03 | AR, CFTR, ESR1, ESR2, FLT3, GSK3B, HIF1A, MAPT, MMP9, NFKB1, NOX4, PTPN1, SYK, TNKS, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.384E-05 | 3.460E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.384E-05 | 3.460E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.384E-05 | 3.460E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 3.189E-05 | 4.395E-03 | ALOX15, CFTR, CYP19A1, CYP1A1, CYP3A4, PKM, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.421E-05 | 4.656E-03 | ABCG2, ACHE, CSNK2A1, ESR1, ESR2, FLT3, MAPT, MMP9, NFKB1, PKM, PTGS2, TP53, TTR, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.716E-05 | 4.994E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0050790; regulation of catalytic activity | 4.041E-05 | 5.399E-03 | AR, CSNK2A1, ESR1, FLT3, GSK3B, HIF1A, MAPT, MMP9, NFKB1, NOX4, PRKCA, PTGS2, PTPN1, SYK, TNKS, TP53, TSHR, XDH |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 4.207E-05 | 5.559E-03 | ALOX15, ESR1, GSK3B, MAPT, MMP1, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 4.759E-05 | 5.990E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.759E-05 | 5.990E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.759E-05 | 5.990E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.759E-05 | 5.990E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 5.331E-05 | 6.634E-03 | ALOX15, AR, CDK6, CYP19A1, ESR1, ESR2, GSK3B, HIF1A, LMNA, MMP9, NFKB1, PTGS2, PTPN1, XDH |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 5.422E-05 | 6.708E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 5.517E-05 | 6.787E-03 | ALOX15, GSK3B, HIF1A, MAPT, MMP9, NOX4, TNKS, TNKS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 5.817E-05 | 7.076E-03 | ALOX15, FLT3, GSK3B, HIF1A, NFKB1, PRKCA, PTGS2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 6.087E-05 | 7.283E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 6.459E-05 | 7.644E-03 | AR, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 6.804E-05 | 7.923E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 6.804E-05 | 7.923E-03 | MAPT, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 7.176E-05 | 8.312E-03 | CSNK2A1, GSK3B, PRKCA, TNKS |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 7.908E-05 | 8.932E-03 | AR, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, MAPT, MMP9, NFKB1, NPC1, PRKCA, PTGS2, PTPN1, THRB, TNKS, TNKS2, TP53, USP2, XDH |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.917E-05 | 8.932E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 8.317E-05 | 9.213E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 8.335E-05 | 9.213E-03 | CDK6, GSK3B, HIF1A, MAPT, PTGS2, PTPN1, SYK, TP53, XDH |
| BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 8.601E-05 | 9.364E-03 | CYP1B1, HIF1A, MMP2, PRKCA, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 8.726E-05 | 9.365E-03 | AR, CSNK2A1, ESR1, GSK3B |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 8.919E-05 | 9.520E-03 | CSNK2A1, CYP1B1, ESR1, GSK3B, MAPT, MMP9, NFKB1, PRKCA, PTGS2, PTPN1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.280E-05 | 9.857E-03 | ABCC1, ALOX15, SYK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.372E-23 | 9.520E-19 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.455E-19 | 1.782E-15 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.486E-16 | 2.389E-12 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.036E-14 | 8.265E-11 | AR, CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, MMP1, MMP2, MMP9, PRKCA, PTPN1, THRB, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.992E-22 | 3.386E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.446E-10 | 5.479E-08 | AR; GSK3B; CDK6; FLT3; MMP1; MMP2; PRKCA; PTGS2; HIF1A; TP53; MMP9; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.184E-08 | 6.710E-07 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.518E-07 | 8.560E-06 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.741E-08 | 4.140E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.498E-07 | 2.408E-05 | GSK3B; THRB; PRKCA; TP53; ESR1; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.430E-06 | 3.039E-05 | ABCC1; CDK6; CYP1B1; PRKCA; PTGS2; TP53; MMP9; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.345E-06 | 8.169E-05 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.946E-05 | 2.757E-04 | MMP2; PRKCA; TP53; HIF1A; ESR1; MMP9 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.155E-06 | 2.805E-05 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.401E-05 | 2.165E-04 | MAOA; ALOX15; PRKCA; CYP2C19; PTGS2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.805E-06 | 8.169E-05 | MMP1; MMP2; MMP9; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.576E-05 | 4.342E-04 | GSK3B; CDK6; CSNK2A1; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.449E-05 | 4.342E-04 | PKM; FLT3; TP53; HIF1A |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 5.019E-05 | 4.491E-04 | CDK6; PRKCA; TP53; MMP9; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.583E-05 | 4.491E-04 | GSK3B; ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.875E-05 | 4.391E-04 | MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.106E-04 | 8.177E-04 | PKM; MAOA; HSD17B1; CYP1A2; ALOX15; CYP1A1; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.337E-05 | 4.491E-04 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.839E-05 | 4.491E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.051E-04 | 8.119E-04 | GSK3B; AR; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.194E-05 | 7.443E-04 | CDK6; PTGS2; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.309E-04 | 1.501E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.587E-04 | 1.079E-03 | MMP2; ESR1; MMP9; ESR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.472E-04 | 1.501E-03 | CDK6; PKM; SYK; TP53; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.372E-04 | 1.911E-03 | GSK3B; CDK6; SYK; PRKCA; TP53; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.246E-04 | 8.827E-04 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.319E-04 | 1.911E-03 | ABCC1; PRKCA; TP53; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.273E-04 | 3.332E-03 | GSK3B; CSNK2A1; PRKCA; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.920E-04 | 2.698E-03 | CDK6; PRKCA; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.619E-04 | 3.700E-03 | CDK6; PRKCA; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.513E-03 | 6.431E-03 | FLT3; TP53; MMP9; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.068E-03 | 4.778E-03 | GSK3B; SYK; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.711E-03 | 1.097E-02 | MMP2; PRKCA; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.966E-04 | 3.762E-03 | CDK6; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.068E-03 | 4.778E-03 | CDK6; TP53; NFKB1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.111E-03 | 4.843E-03 | CA2; PRKCA; CFTR |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.635E-04 | 3.418E-03 | ALOX15; CYP2C19; PTGS2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.619E-04 | 3.700E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.866E-03 | 1.133E-02 | PRKCA; HIF1A; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.450E-03 | 1.303E-02 | PTGS2; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.362E-03 | 1.299E-02 | PTPN1; GSK3B; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 5.290E-03 | 1.831E-02 | PRKCA; MAPT; TP53; NFKB1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.406E-04 | 1.501E-03 | ABCC1; CFTR; ABCG2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.347E-03 | 9.730E-03 | CA2; PRKCA; CFTR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.404E-03 | 1.593E-02 | GSK3B; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.753E-03 | 2.208E-02 | LMNA; TP53; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 4.201E-03 | 1.553E-02 | MMP2; PRKCA; MMP9 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 5.386E-03 | 1.831E-02 | GSK3B; MAOA; PRKCA |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 4.825E-03 | 1.709E-02 | GSK3B; CDK6; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.861E-03 | 1.954E-02 | GSK3B; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.110E-02 | 3.092E-02 | GSK3B; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.238E-02 | 3.289E-02 | GSK3B; PRKCA; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.437E-02 | 3.700E-02 | CSNK2A1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.743E-02 | 4.058E-02 | CFTR; NFKB1; TSHR |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.506E-02 | 3.766E-02 | SYK; PRKCA |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.040E-02 | 2.996E-02 | PTGS2; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.187E-02 | 3.254E-02 | PRKCA; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.635E-02 | 3.914E-02 | CDK6; TP53 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.225E-02 | 3.289E-02 | PRKCA; PTGS2 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.076E-02 | 3.048E-02 | FLT3; NFKB1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 1.464E-02 | 3.716E-02 | MAOA; PRKCA |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.016E-03 | 2.689E-02 | GSK3B; TP53 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.723E-02 | 4.058E-02 | PTGS2; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.264E-02 | 3.305E-02 | GSK3B; TP53 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.767E-02 | 4.060E-02 | PTPN1; CSNK2A1 |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 1.635E-02 | 3.914E-02 | PRKCA; TSHR |
| hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.548E-02 | 3.815E-02 | CDK6; TP53 |
| hsa05110 | Vibrio cholerae infection_Homo sapiens_hsa05110 | 8.685E-03 | 2.636E-02 | PRKCA; CFTR |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.004E-02 | 2.944E-02 | GSK3B; TP53 |
| hsa04961 | Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | 7.415E-03 | 2.334E-02 | PRKCA; ESR1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 8.039E-03 | 2.485E-02 | MAOA; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 7.112E-03 | 2.281E-02 | CYP3A4; XDH |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.386E-05 | 6.278E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; XDH; ABCC1; ABCC1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; GSK3B; ACHE; ACHE; ACHE; MAOA; MAPT |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; FLT3; CA9; MMP9; MMP2; PKM |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; SYK; MMP1 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; SYK |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; MMP1; ABCC1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; SYK; SYK |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESR1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; FLT3; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; AR; ACHE; ESR1; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; ESR1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; AR; GSK3B; HIF1A; SYK; TP53; CA1; FLT3; FLT3; CA9; MMP9; ACHE; NFKB1; MMP2; ESR1; ESR1; CSNK2A1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |